NCT03721510View on ClinicalTrials.gov

A Phase 1/2a Study of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

December 3, 2018

Primary Completion Date

October 25, 2021

Study Completion Date

May 2, 2022

Conditions
HIV/AIDS
Interventions
BIOLOGICAL

PGT121 + VRC07-523LS

PGT121 + VRC07-523LS, dose 30 mg/kg each, given intravenously

BIOLOGICAL

PGT121 + VRC07-523LS + PGDM1400

PGT121 + VRC07-523LS + PGDM1400, dose 20 mg/kg each, given intravenously

Trial Locations (3)

32803

Orlando Immunology Center, Orlando

77030

Houston AIDS Research Team (HART), Houston

02215

Center for Virology and Vaccine Research/ Clinical Trials Unit/ BIDMC, Boston

All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Orlando Immunology Center

OTHER

collaborator

Houston AIDS Research Team

UNKNOWN

lead

International AIDS Vaccine Initiative

NETWORK

NCT03721510 - A Phase 1/2a Study of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults | Biotech Hunter | Biotech Hunter